Download PDF
TumorDiagnostik & Therapie 2019; 40(10): 659-662
DOI: 10.1055/a-0961-9775
Schwerpunkt Zell- und Gentherapie
© Georg Thieme Verlag KG Stuttgart · New York

Zell- und Gentherapie bei soliden Tumoren

Matthias Theobald
Further Information

Publication History

Publication Date:
29 November 2019 (online)

Also available at
    Permissions and Reprints

Die mit der CAR-T-Zell-Therapie bei hämatologischen Malignomen erzielten Erfolge ließen sich bei soliden Tumoren bislang nicht realisieren. Aber aktuelle Entwicklungen bei der Wahl der passenden Antigene und CAR-T-Zellen der 4. Generation als Vehikel machen jetzt Hoffnung auf Abhilfe. Ein Blick auf die aktuelle Entwicklung.
 

  • Literatur

  • 1 Louis CU, Savoldo B, Dotti G. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050-6056
    CrossrefPubMedSearch in Google Scholar
  • 2 Ahmed N, Brawley VS, Hegde M. et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigenreceptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015; 33: 1688-1696
    CrossrefPubMedSearch in Google Scholar
  • 3 Brown CE, Alizadeh D, Starr R. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375: 2561-2569
    CrossrefPubMedSearch in Google Scholar
  • 4 Hegde M, Mukherjee M, Grada Z. et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 2016; 126: 3036-3052
    CrossrefPubMedSearch in Google Scholar
  • 5 Kloss CC, Condomines M, Cartellieri M. et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31: 71-75
    CrossrefPubMedSearch in Google Scholar
  • 6 Roybal KT, Williams JZ, Morsut L. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016; 167: 419-432
    CrossrefPubMedSearch in Google Scholar
  • 7 Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 2018; 173: 1426-1438
    CrossrefPubMedSearch in Google Scholar
  • 8 D’Aloia MM, Zizzari IG, Sacchetti B. et al. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis 2018; 9: 282
    CrossrefPubMedSearch in Google Scholar
  • 9 Kosti P, Maher J, Arnold JN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol 2018; 9: 1104
    CrossrefPubMedSearch in Google Scholar
  • 10 Smith TT, Moffett HF, Stephan SB. et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest 2017; 127: 2176-2191
    CrossrefPubMedSearch in Google Scholar
  • 11 Pule MA, Savoldo B, Myers GD. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-1270
    CrossrefPubMedSearch in Google Scholar
  • 12 Gargett T, Yu W, Dotti G. et al. GD2-specific CAR T Cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 2016; 24: 1135-1149
    CrossrefPubMedSearch in Google Scholar
  • 13 O’Rourke DM, Nasrallah MP, Desai A. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9: eaaa0984
    CrossrefPubMedSearch in Google Scholar
  • 14 Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 2017; 21: 3205-3219
    CrossrefPubMedSearch in Google Scholar
  • 15 Zhang L, Yu Z, Muranski P. et al. Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 2013; 20: 575-580
    PubMedSearch in Google Scholar
  • 16 Hoeller C, Michielin O, Ascierto PA. et al. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother 2016; 65: 1015-1034
    CrossrefPubMedSearch in Google Scholar
  • 17 Andtbacka RH, Kaufman HL, Collichio F. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015; 33: 2780-2788
    CrossrefPubMedSearch in Google Scholar
  • 18 Chesney J, Puzanov I, Collichio F. et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 2018; 36: 1658-1667
    CrossrefPubMedSearch in Google Scholar
  • 19 Sahin U, Derhovanessian E, Miller M. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547: 222-226
    PubMedSearch in Google Scholar
  • 20 Schumacher T, Bunse L, Pusch S. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512: 324-327
    CrossrefPubMedSearch in Google Scholar
  • 21 Schmidts A, Maus MV. Making CAR t cells a solid option for solid tumors. Frontiers in Immunology 2018; 9: 2593
    CrossrefPubMedSearch in Google Scholar
  • 22 Li J, Li W, Huang K. et al. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol 2018; 11: 22
    CrossrefPubMedSearch in Google Scholar